Total Holdings
52
As of Oct 4, 2026
First Trust Nasdaq Pharmaceuticals ETF
FTXHNASDAQFirst TrustEquity
$43.12Today:- (-)1Y +46.83%
As of Oct 27, 2026 close
- Assets (AUM)
- $1.08B
- Expense ratio
- 0.60%
- Dividend yield
- 0.67%
- Holdings
- 52
- 52-week range
- $29.25$43.52
- Volume (live)
- -
- Avg. volume (3M)
- 256.39K
FTXH ETF Holdings: First Trust Nasdaq Pharmaceuticals ETF
Every listed position with its portfolio weight, plus sector breakdown and geographic exposure for this Equity ETF. Analyze fund diversification and concentration.
Top 10 Holdings
58.1%
Share of fund assets
Assets (AUM)
$1.08B
Total fund assets
Expense Ratio
0.60%
Annual management fee
Portfolio Allocations
Distribution breakdown by sector, asset type, and geographic region. Understand the fund's diversification strategy across markets and asset classes.
Loading chart...
Top 49 of 52 FTXH Holdings by Portfolio Weight
Holdings as of Oct 4, 2026. Ticker, name, asset type and portfolio weight for each position. Fund disclosures available to us list the largest 49 positions.
Scroll to see more
| # | Symbol | Name | Type | Weight |
|---|---|---|---|---|
| 1 |  | Merck & Co., Inc | Stock | 7.58% |
| 2 |  | Eli Lilly and Company | Stock | 7.43% |
| 3 |  | AbbVie Inc. | Stock | 7.37% |
| 4 |  | Pfizer Inc. | Stock | 7.18% |
| 5 |  | Johnson & Johnson | Stock | 7.07% |
| 6 |  | Bristol-Myers Squibb Company | Stock | 6.61% |
| 7 |  | Viatris Inc. | Stock | 3.84% |
| 8 |  | Biogen Inc. | Stock | 3.74% |
| 9 |  | Gilead Sciences, Inc. | Stock | 3.66% |
| 10 |  | United Therapeutics Corporation | Stock | 3.61% |
| 11 |  | Amgen Inc | Stock | 3.53% |
| 12 |  | Vertex Pharmaceuticals Incorporated | Stock | 3.43% |
| 13 |  | Incyte Corporation | Stock | 3.42% |
| 14 |  | Regeneron Pharmaceuticals, Inc | Stock | 3.34% |
| 15 |  | Zoetis Inc. | Stock | 3.26% |
| 16 |  | Cardinal Health, Inc | Stock | 3.14% |
| 17 |  | Jazz Pharmaceuticals plc | Stock | 2.69% |
| 18 |  | Exelixis, Inc. | Stock | 2.35% |
| 19 |  | Illumina, Inc. | Stock | 2.23% |
| 20 |  | Charles River Laboratories International, Inc | Stock | 1.77% |
| 21 |  | Halozyme Therapeutics, Inc. | Stock | 1.56% |
| 22 |  | Medpace Holdings, Inc | Stock | 1.50% |
| 23 |  | Twist Bioscience Corporation | Stock | 1.26% |
| 24 |  | BioMarin Pharmaceutical Inc. | Stock | 1.24% |
| 25 |  | Neurocrine Biosciences, Inc. | Stock | 1.21% |
| 26 |  | 10x Genomics, Inc | Stock | 1.20% |
| 27 |  | Alnylam Pharmaceuticals, Inc. | Stock | 1.20% |
| 28 |  | Alkermes plc | Stock | 1.15% |
| 29 |  | Elanco Animal Health Incorporated | Stock | 1.14% |
| 30 |  | PTC Therapeutics, Inc | Stock | 1.10% |
| 31 |  | Spyre Therapeutics Inc. | Stock | 1.08% |
| 32 |  | Moderna, Inc | Stock | 1.08% |
| 33 |  | Travere Therapeutics Inc | Stock | 0.94% |
| 34 |  | Guardant Health, Inc | Stock | 0.78% |
| 35 |  | TG Therapeutics, Inc | Stock | 0.73% |
| 36 |  | Protagonist Therapeutics Inc | Stock | 0.71% |
| 37 |  | Amneal Pharmaceuticals, Inc | Stock | 0.66% |
| 38 |  | Arrowhead Pharmaceuticals, Inc | Stock | 0.65% |
| 39 |  | Arcus Biosciences, Inc | Stock | 0.63% |
| 40 |  | Ligand Pharmaceuticals Incorporated | Stock | 0.62% |
| 41 |  | Kymera Therapeutics, Inc | Stock | 0.58% |
| 42 |  | Roivant Sciences Ltd | Stock | 0.55% |
| 43 |  | Krystal Biotech, Inc | Stock | 0.53% |
| 44 |  | ACADIA Pharmaceuticals Inc | Stock | 0.51% |
| 45 |  | Mirum Pharmaceuticals Inc | Stock | 0.46% |
| 46 |  | Tarsus Pharmaceuticals Inc | Stock | 0.41% |
| 47 |  | Arcutis Biotherapeutics, Inc | Stock | 0.41% |
| 48 |  | Supernus Pharmaceuticals, Inc | Stock | 0.37% |
| 49 |  | Ionis Pharmaceuticals, Inc | Stock | 0.31% |
Source: Fund holdings disclosures. Data as of Oct 4, 2026. Data sources and methodology
Frequently Asked Questions About First Trust Nasdaq Pharmaceuticals ETF Holdings
What are the top holdings in FTXH?
As of Oct 4, 2026, First Trust Nasdaq Pharmaceuticals ETF (FTXH) holds 52 securities. The largest are Merck & Co., Inc (7.58%), Eli Lilly and Company (7.43%), AbbVie Inc. (7.37%). The holdings table lists each position by portfolio weight with its ticker, name and asset type.
How concentrated is FTXH's portfolio?
As of Oct 4, 2026, the 10 largest positions make up 58.1% of FTXH's assets. A concentrated portfolio has fewer large positions with higher individual weights, while a diversified portfolio distributes holdings more evenly.
What is FTXH's sector allocation?
The Sector Allocation chart shows how FTXH distributes investments across different industries like Technology, Healthcare, Financials, and more. This sector exposure helps understand the fund's industry diversification strategy.
What countries does FTXH invest in?
FTXH's geographic exposure is shown in the Countries tab under Portfolio Allocations. This reveals the fund's international diversification and exposure to different regions and global markets.
How diversified is FTXH ETF?
FTXH's diversification can be assessed by reviewing its 52 holdings (as of Oct 4, 2026), sector allocation, and geographic exposure. A well-diversified ETF spreads investments across multiple securities, sectors, and regions to reduce concentration risk.